

UNITED STATES OF AMERICA
before the
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934
Release No. 86405 / July 18, 2019

Admin. Proc. File No. 3-19242

In the Matter of
APOTHECA BIOSCIENCES INC.

CORRECTED ORDER REQUESTING ADDITIONAL WRITTEN SUBMISSIONS

On June 28, 2019, the Commission issued an order pursuant to Section 12(k) of the Securities Exchange Act of 1934 suspending trading in the securities of Apotheca Biosciences Inc. (“CBDC”) (CIK No. 0001632053) through July 15, 2019 (the “Trading Suspension Order”).¹ The Commission stated that there appeared to be “a lack of current and accurate information concerning the securities” of Apotheca “because of questions regarding the accuracy of assertions by Apotheca . . . , and by others, in press releases and/or cold calls to investors concerning, among other things: (1) corporate assets; (2) anticipated corporate acquisitions; (3) business operations; and (4) up-listing to the OTCQB.”² The Commission was therefore “of the opinion that the public interest and the protection of investors require a suspension of trading.”³

On July 9, 2019, Apotheca filed a petition to terminate the trading suspension. In accordance with Rule of Practice 550(b), additional written submissions are requested.⁴

Accordingly, IT IS ORDERED that the parties file submissions as follows:

- By August 7, 2019, the Division of Enforcement shall file all the information that was before the Commission at the time of the Trading Suspension Order’s issuance.⁵

¹ *Apotheca Biosciences Inc.*, Exchange Act Release No. 86248, 2019 WL 2726232 (June 28, 2019).

² *Id.* at *1.

³ *Id.*

⁴ 17 C.F.R. § 201.550(b).

- By August 21, 2019, Apotheca shall file an opening brief, which is not to exceed 8,000 words.
- By September 4, 2019, the Division shall file an answering brief, which is not to exceed 8,000 words.
- By September 11, 2019, Apotheca may file an optional reply brief, which is not to exceed 3,000 words.

Any evidentiary materials, such as supporting affidavits or declarations, shall be attached to the briefs, which must contain specific citations to the evidence relied upon. No briefs in addition to those specified in this order may be filed without leave of the Commission.⁶

Pursuant to Rule of Practice 180(c), a party's failure to file a brief or to comply with this order may result in the Commission's determination of the matter at issue against that party, a finding of waiver, dismissal of the proceeding, or such other sanction as the Commission finds appropriate.⁷

For the Commission, by the Office of the General Counsel, pursuant to delegated authority.

Vanessa A. Countryman
Secretary

⁵ See 15 U.S.C. § 78l(k)(5). The Division need not disclose privileged legal analysis or sensitive information about the staff's investigative methods.

⁶ The briefs shall conform to Rules of Practice 150-153, with respect to service, filing, and form, and Rule of Practice 450(b)-(d), with respect to content and length limitations, except as modified in this order. 17 C.F.R. §§ 201.150-153, 201.450(b)-(d).

⁷ 17 C.F.R. § 201.180(c).